Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_001127208.2 | RefSeq Select | 9796 nt | 488–6496 |
| NM_001127208.3 | MANE Select | 9589 nt | 297–6305 |
| NM_001127208.1 | Alternative | 9677 nt | 387–6395 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
Open""
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: TET2R1262WTET2R1262WSomaticNCBI Gene:54790|Show additional gene information Variant OverviewTET2, a tumor suppressor and DNA demethylase, is frequently mutated in hematologic malignancies.The TET2 R1262W mutation has not specifically been reviewed by the OncoKB team. While TET2 R1262A is likely neutral, the oncogenic effect of TET2 R1262W is unknown.Hide mutation effect description The TET2 R1262W mutation has not specifically been reviewed by the OncoKB team. However, the mutation effect description for TET2 R1262A, an alternate allele of TET2 R1262W, is: The TET2 R1262A mutation is located at a residue involved in the hydrogen binding of methylated cytosine (m6C) in substrate DNA. In vitro studies with HEK293T cells expressing this mutation demonstrate TET2 R1262A is likely neutral as measured by minimal effect on enzymatic activity compared to wildtype (PMID: 24315485). JAX-CKB: No results found
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.02 | -80 bp |
| Donor Loss (DL) | 0.0 | 19 bp |
| Acceptor Gain (AG) | 0.0 | -211 bp |
| Donor Gain (DG) | 0.0 | 1 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PS3 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
BP4 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)